Edoxaban cost-effective option in NVAF

Mearns E, et al. Cost-effectiveness of high-dose edoxaban compared to adjusted-dose warfarin for prevention of stroke and systemic embolism in non-valvular atrial fibrillation. ESC Congress 2014: Annual Congress of the European Society of Cardiology : abstr. 5110, 14 Aug 2014. Available from: URL: http://www.escardio.org/congresses/esc-2014